In March, workers at Emergent’s Baltimore plant accidentally conflated the ingredients of Johnson & Johnson’s COVID-19 vaccine, ruining about 15 million doses and prompting a monthslong shutdown.
Emergent will relinquish about $180 million because of the deal’s termination, according to company disclosures.
The drugmaker said it will continue working with Johnson & Johnson to produce its vaccine in Baltimore, as the deal between the drugmakers was not financed under the U.S. deal.
The Baltimore plant has not yet secured regulators’ approval, but it has resumed manufacturing and the FDA has allowed about 100 million doses to be released for potential administration, according to The New York Times.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.